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Edited by Laszlo NagyAbstract The liver X receptors (LXRs) function as nutritional
sensors for cholesterol and have important roles in lipid metabo-
lism, glucose homeostasis, and inﬂammation. We provide the
ﬁrst evidence that LXRs are phosphorylated proteins. Muta-
tional analysis and metabolic labeling indicate LXRa is phos-
phorylated on serine 198 in the hinge region. This is a
consensus target for the MAPK family. A phosphorylation-deﬁ-
cient mutant, LXRa S198A, remains nuclear and responds to li-
gands like the wild-type protein. The biological signiﬁcance of
LXR phosphorylation remains to be elucidated but could provide
a novel mechanism for the regulation of LXR signaling pathways
and cellular metabolism.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Phosphorylation1. Introduction
The liver X receptors (LXRa and LXRb) have emerged as
important regulators of cholesterol metabolism and transport
[1]. LXRa is primarily expressed in liver, macrophages, adipose
tissue, and the intestinal epithelium. LXRb is ubiquitously ex-
pressed. LXRs function as total body sterol sensors, regulating
both cholesterol homeostasis and lipogenesis [2]. The physio-
logic ligands for LXRs are oxysterols and intermediates in
the cholesterol biosynthetic pathway [3,4]. In macrophages,
LXRs integrate the response to cellular cholesterol loading
and promote reverse cholesterol transport to the liver. They di-
rect transcription of several target genes involved in the choles-
terol eﬄux pathway and repress some inﬂammatory genes in
macrophages [5–7]. LXRs have also been shown to regulate
several genes involved in hepatic fatty acid synthesis [8,9].
Previous work has linked LXR signaling to the development
of metabolic diseases. Chronic administration of a synthetic
LXR ligand signiﬁcantly reduced atherosclerosis in both
LDLR / and apoE / mice [10]. Furthermore, LXRs
are essential for proper cholesterol eﬄux from macrophagesAbbreviations: LXR, Liver X Receptor; MAPK, mitogen-activated
protein kinase; LDLR, low-density lipoprotein receptor; apoE, apo-
lipoprotein E
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in mice [11]. These studies identify LXRs as atheroprotective
factors in vivo and directly link LXR activity to the pathogen-
esis of this disease.
Post-translational modiﬁcations such as phosphorylation
have been shown to be important regulatory mechanisms for
a number of nuclear receptors [12–17]. Here, we establish for
the ﬁrst time that LXRs are phosphorylated proteins. Moreover,
we show that LXRa is phosphorylated at a single site (S198) in
the hinge region of the protein. This serine is a consensus site
for mitogen-activated protein kinase (MAPK) phosphory-
lation. LXR phosphorylation may constitute a novel mecha-
nism for regulation of LXR-dependent metabolic pathways.2. Materials and methods
2.1. Reagents
Synthetic LXR ligand, T0901317, was provided by Tim Willson
(GlaxoSmithKline). Anti-LXRa antibodies were a generous gift of
Jae Bum Kim (Seoul National University, Korea). Orthophosphate
(32P) for metabolic labeling experiments was from Amersham. All
other chemicals, unless otherwise noted, were from Sigma–Aldrich.
2.2. Plasmid constructs
Full-length coding regions of human LXRa or LXRb were ampliﬁed
by PCR using gene-speciﬁc primers and subcloned into BamHI/KpnI
restriction sites of the following mammalian expression vectors: pShut-
tle (Stratagene), pCMX, and pEGFP. In some cases, the inserts were
epitope-tagged with one to three tandem repeats of the FLAG octa-
peptide (DYKDDDDK) at the N-terminus for identiﬁcation by immu-
noblotting. Deletional mutations for the AF1 (DAF1) and hinge
regions (DHinge) of hLXRa were made as previously described [18].
For retroviral expression constructs, inserts were subcloned into Bam-
HI/SalI sites of the pBabe-Puro vector. Site-directed mutagenesis of
wild-type hLXRa was carried out using the QuikChange II method
(Stratagene). Sequences of all plasmids were veriﬁed by direct DNA
sequencing.
2.3. Cell culture
HEK-293 andRAW264.7 macrophages were grown in DMEM (Gib-
co) supplemented with 10% fetal bovine serum (FBS). For ligand treat-
ments, cells were cultured in RPMI or DMEM medium supplemented
with either 10% lipoprotein-deﬁcient serum (Intracel) or 1% FBS (low
serum) and the appropriate concentration of T0901317. In some exper-
iments, cells were sterol depleted by adding 5 lM simvastatin (Calbio-
chem) and 100 lM mevalonic acid during the treatment period.
2.4. Transfections and promoter activity assays
For transient transfections, HEK-293 cells were plated at a density
of 5 · 104 cells per well on poly-D-lysine coated 48-well plates. After
24 h, cotransfections were performed by either the calcium phosphate
method or using the transfection reagent, Lipofectamine 2000 (Invitro-
gen). The luciferase reporter was under the control of the rat fatty acidblished by Elsevier B.V. All rights reserved.
4836 M. Chen et al. / FEBS Letters 580 (2006) 4835–4841synthase (rFAS) promoter. A renilla luciferase reporter served as an
internal control for transfection eﬃciency. After 24–48 h in ligand-con-
taining or control media, the cells were harvested in lysis buﬀer and
luciferase expression was analyzed by the dual-luciferase assay (Prome-
ga), according to the manufacturer’s protocol.A
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Fig. 1. Generation of stable cell lines. (A) Expression of FLAG-tagged hLX
FLAG and anti-LXRa antibodies. (B) Northern blot analysis of RAW cells
expression in RAW cells.
CIP
Fla
g-L
XR
Fla
g-L
XR
- +   - +
A
Mo
ck
LX
R
IP:  anti-Phosp
WB:  anti-Flag
B
Fig. 2. LXRs are phosphoproteins. (A) Enzymatic dephosphorylation with c
LXRa and LXRb. (B) Co-immunoprecipitation with anti-phosphoserine an2.5. Stable cell lines
FLAG-tagged human LXRa, S198A mutant and LXRb were cloned
into the pBabe-Puro expression vector and packaged into retrovirus by
transient transfection of Phoenix E cells. HEK-293 cells or RAW 264.7
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(2 lg/ml) after 2 weeks of growth. At least two independently derived
cell lines were selected to conﬁrm reproducibility of results.hLXRa Reverse 5 0 ﬁ 3 0 CTGGCTGCTTGCAT-
CCTGT
mABCA1 Forward 5 0 ﬁ 3 0 GGTTTGGAGATGGTT-
ATACAATAGTTGT
mABCA1 Reverse 5 0 ﬁ 3 0 CCCGGAAACGCAAGTCC
mABCG1 Forward 5 0 ﬁ 3 0 TCACCCAGTTCTGCA-
TCCTCTT
mABCG1 Reverse 5 0 ﬁ 3 0 GCAGATGTGTCAGGA-
CCGAGT2.6. Quantitative PCR and Northern blot analysis
After lysis in TRIzol Reagent (Life Technologies), total cellular
RNA was reverse-transcribed into cDNA according to the manufac-
turer’s protocol using a reverse transcription kit (Roche Molecular
Systems). Real-time, quantitative PCR assays for mRNA transcript
levels were performed using a Sybergreen-based chemistry as described
previously [19]. Samples were analyzed simultaneously for 36B4
expression as the internal control. Quantitative expression values were
extrapolated from separate standard curves. Each sample was assayed
in duplicate and normalized to 36B4. The sequences for qPCR primers
are as follows:Gene Primer Direction qPCR primer sequence
m36B4 Forward 5 0 ﬁ 3 0 AGATGCAGCAGATC-
CGCAT
m36B4 Reverse 5 0 ﬁ 3 0 GTTCTTGCCCATCAG-
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Fig. 3. The major phosphorylation site of LXRa is S198. (A) Schematic rep
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the protein. (D) S198 is the major phosphorylation site for hLXRa.For Northern blots, 10 lg of total cellular RNA was separated by
gel electrophoresis, transferred to nylon membranes, and hybridized
with [32P]dCTP-labeled DNA probes speciﬁc for human 36B4, LXRa,
and ABCA1 [19]. Blots were normalized using cDNA probes to
36B4 and quantiﬁed by PhosphorImager (Molecular Dynamics)
analysis.
2.7. Immunoprecipitation and western blot analysis
FLAG-tagged human LXRa and LXRb were stably expressed in
HEK-293 cells and immunoprecipitated from lysates with anti-FLAG
antibody-coated beads (Sigma). Total cellular protein (50–100 lg) wasS198, S207
DBD LBD -C
171 264 447
Hinge
ΔHinge
DBD LBD -C
171 264 447
Hinge
BD LBD -C
171 264 447197 246
W
T
S1
97
/1
98
/2
07
A
W
T
S2
07
A
S1
98
A
S1
98
/2
07
A
M
oc
k
D
resentation of the various deletion and point mutants of hLXRa. (B)
ation of hLXRa (S197, S198, and S207) eliminates phosphorylation of
hLXRα
WT
1 μM  T1317DMSO
4838 M. Chen et al. / FEBS Letters 580 (2006) 4835–4841loaded onto 10% agarose gels, separated by SDS–PAGE, and trans-
ferred onto PVDF membranes. Immunoblotting was performed with
rabbit anti-phosphoserine antibodies (Zymed). Secondary antibodies
were HRP-conjugated anti-rabbit IgG. The signal was detected using
standard chemiluminescence techniques in accordance to the manufac-
turer’s protocol (Amersham). In complementary experiments, immu-
noprecipitation was ﬁrst performed with a rabbit anti-phosphoserine
polyclonal antibody (Zymed) followed by detection with anti-FLAG
immunoblotting.
2.8. Immunocytochemistry
Both wild-type hLXRa and hLXRa S198A were cloned in frame to
a green ﬂuorescent protein in the pEGFP vector. HEK-293 cells were
transiently transfected with these constructs and treated for 8 h with
1 lMT0901317 or vehicle (DMSO). Subcellular localization was deter-
mined by ﬂuorescence microscopy (Carl Zeiss Microimaging). Results
are typical of n = 3 repetitions, where transfection eﬃciency was 95–
100%.
2.9. In vitro phosphatase assay
FLAG-tagged human LXRs were puriﬁed by immunoprecipitation
with anti-FLAG antibody beads as described above. Approximately
5–10 lg of the precipitated protein was diluted in 100 ll of phospha-
tase reaction buﬀer (20 mM HEPES [pH 7.2]; 150 mM NaCl, 10 mM
MgCl2, 0.1% (v/v) Triton X-100, 10% (v/v) glycerol), and then treated
with calf intestinal phosphatase (CIP), 5 U, at 30 C for 1 h. Control
reactions did not include the phosphatase. Equal amounts of protein
were separated by SDS–PAGE and transferred to PVDF membranes.
The protein was detected with anti-FLAG antibodies and visualized by
chemiluminescent techniques.
2.10. Metabolic labeling
Two sets of conﬂuent HEK-293 cells were transfected with 4 lg of
plasmid encoding the respective proteins. One set of cells was kept in
phosphate-free DMEM supplemented with 10% dialyzed FBS (Omega
Scientiﬁc) and 1.0–2.5 mCi/mL 32P-orthophosphate for 4 h. The other
set was not labeled and was harvested for parallel Western blot analy-
sis. Cells were resuspended in 1 mL of lysis buﬀer (50 mM Tris, pH 7.4,
150 mM NaCL, 1 mM EDTA, 1% Triton X-100) supplemented with a
protease inhibitor cocktail (Sigma) and placed on ice for 30 min. After
centrifugation, 500 ll of extract was used to immunoprecipitate pro-
teins using anti-FLAG beads. Proteins were separated by SDS–PAGE
and transferred to nitrocellulose membranes. Labeled proteins were
detected by autoradiography. The parallel, unlabeled proteins were de-
tected by standard Western blot analysis.hLXRα
S198A      
hLXRβ
WT
Fig. 4. Localization of GFP-hLXRa in HEK-293 cells. HEK-293 cells
transiently expressing GFP-fusion proteins of hLXRa WT, S198A, or
hLXRb were treated with or without LXR ligand (T0901317, 1 lM)
for 8 h prior to ﬁxation and DAPI staining. GFP-LXR fusion proteins
are visualized by ﬂuorescence microscopy (100·).3. Results
We used a model system in which epitope-tagged LXRs were
stably expressed in vitro. The expression of FLAG-tagged pro-
teins was conﬁrmed by immunoblotting with anti-FLAG and
anti-LXRa antibodies (Fig. 1A). LXRa migrates as a major
band at 50kD, and a second band at 52 kD, suggestive of a
post-translational modiﬁcation. Induction of the ABCA1 tar-
get gene conﬁrmed functional expression of the receptor
(Fig. 1B,C). Robust induction of ABCA1 was observed in
response to the synthetic LXR agonist T0901317 (Fig. 1B, lane
4). It should be noted that RAW cells do not express LXRa
endogenously, but do have basal levels of LXRb [20]. There-
fore, baseline ABCA1 expression and induction by ligand in
these cells is expected (Fig. 1B,C).
Next, we investigated whether LXR proteins are phosphor-
ylated in the steady state. Treatment of cell extracts with calf
intestinal phosphatase (CIP) from stably transfected RAW
cells led to a subtle, but distinct, mobility shift in bands corre-
sponding to both LXRa and LXRb (Fig. 2A). This observa-
tion strongly suggests that both LXRs are phosphorylatedproteins. We then used an anti-phosphoserine antibody to
show that both LXRa and LXRb contain phosphoserine resi-
dues (Fig. 2B).
The primary amino acid sequences of human LXRa and
LXRb were analyzed by NetPhos 2.0 Server software (http://
www.cbs.dtu.dk/services/NetPhos/). Four proline-directed
phosphorylation sites were identiﬁed by algorithmic predic-
tion: serines 16 and 49 in the AF-1 region and serines 198
and 207 in the hinge region (Fig. 3A). Sequence alignment of
human, mouse, and rat LXRs revealed conservation of these
sites among the diﬀerent species. In human LXRa, serine
198 (PRRSSP) and serine 207 (PQLSP) are predicted consen-
sus sites. Strikingly, serine 198 of LXRa is conserved in the
alignment with serine 196 of LXRb. This is the only putative
phosphorylation site in the protein with conservation among
species and isoforms.
We sought to identify the phosphorylation sites of human
LXRa by making deletion mutants. The DAF1 mutant lacks
amino acids 1–56 of the activating function 1 (AF1) region
and the DHinge mutant lacks amino acids 197–246 of the hinge
region between the DNA binding domain (DBD) and ligand
binding domain (LBD) (Fig. 3A). The DAF1/DHinge mutant
lacks both of these regions. We assayed for phosphorylation
by labeling with [32P]-orthophosphate. As shown in Fig. 3B,
wild-type and deletion constructs express similar protein levels.
Deletion of AF1 does not signiﬁcantly aﬀect phosphorylation,
but deletion of the hinge region completely abolishes it. We
therefore focused our attention on the hinge region of the pro-
M. Chen et al. / FEBS Letters 580 (2006) 4835–4841 4839tein. Fig. 3B indicates that LXRb is also phosphorylated, con-
sistent with the conserved serine in both the a (S198) and b
(S196) isoforms. In the present study, we chose to focus solely
on the site in LXRa.
We made point mutations of the potential phosphorylation
sites in the hinge region. Changing serine to alanine prevents
phosphorylation at the residue. Double point mutations
(S198A, S207A) and a triple mutant (S197A, S198A, S207A)
were also made. Each of the point mutants express at compa-
rable levels in HEK-293 cells (Fig. 3C, D lower panels). The
triple mutant was unable to be phosphorylated in this assay
(Fig. 3C, lane 2), as was the double mutant (Fig. 3D, lane
5). The S207A mutant displayed normal phosphorylation
(Fig. 3D, lanes 2 and 4). By contrast, the S198A single point0.0
0.2
0.4
0.6
0.8
1.0
1.2
R
el
at
iv
e 
Ex
pr
es
si
on ABCA1
0.0
0.2
0.4
0.6
0.8
1.0
pBabe F-hLXRα WT
R
el
at
iv
e 
Ex
pr
es
si
on ABCG1
Endogenous mRNA ex
RAW stable cell l
B
0
1
2
3
4
5
6
7
8
0 1 10 50
Fo
ld
 In
du
ct
io
n
(ov
er
 D
M
SO
 m
oc
k 
co
nt
ro
l)
Concentration T1317 
FAS promoter actiA
Fig. 5. hLXRa wild-type and S198A mutants have similar transactivating
assayed for their ability to transactivate an LXRE-containing luciferase repo
control media for 24 h. Total luciferase expression was normalized to renilla
S198A were treated with LXR ligand or control media for 24 h. cDNA was pr
target gene expression.mutation displayed a complete lack of phosphorylation
(Fig. 3D, lane 3). We deduce that S198 is the sole phosphory-
lation site in hLXRa under these conditions.
To investigate whether phosphorylation aﬀects cellular
localization, GFP fusion proteins of wild-type hLXRa and
the S198A mutant, as well as hLXRb, were expressed in
HEK-293 cells. As shown in Fig. 4, all three constructs localize
to the nucleus in the presence and absence of ligand. We con-
clude that phosphorylation at S198 does not substantially alter
the sub-cellular distribution of the protein and that both LXRs
are constitutively nuclear (as expected).
To determine if phosphorylation alters the ability of the
receptor to activate transcriptional targets, we performed lucif-
erase-based assays using the fatty acid synthase (FAS) pro-0
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expression. (B) RAW macrophages stably expressing hLXRa WT or
epared from total cellular mRNA and analyzed by RT-qPCR for LXR
4840 M. Chen et al. / FEBS Letters 580 (2006) 4835–4841moter [9]. The dose response to synthetic LXR ligand was sim-
ilar between wild-type and S198A hLXRa (Fig. 5A). There is a
consistent trend for the S198A mutant to have less activity at
every dose of ligand, but this diﬀerence did not reach statistical
signiﬁcance.
To determine if phosphorylation is required for the expression
of endogenous target genes, we generated RAW cells stably
expressing either hLXRa wild-type or S198A. These cells were
treated with increasing doses of LXR ligand and target gene
expression was assayed by real-time quantitative PCR. There
was no signiﬁcant diﬀerence in ABCA1 or ABCG1 expression
(Fig. 5B), suggesting that phosphorylation at S198 is not
required for expression of these genes under basal conditions.
To rule out possible diﬀerences based on clone selection, we
repeated the experiments in a second stable pool of hLXRa-
S198A expressing RAW cells and again saw no signiﬁcant
diﬀerence in target gene expression. LXRs are also known to
inhibit several inﬂammatory genes, including iNOS [7], and in
our stably expressing RAW cells, both the wild-type and mutant
form of hLXRa inhibited LPS-induced activation of iNOS
equally well in response to synthetic ligands (data not shown).4. Discussion
In addition to regulation in the presence of ligand, nuclear
receptor activity is also modiﬁed by protein post-translational
modiﬁcations [21]. Phosphorylation of nuclear receptors
appears to be the rule rather than the exception as many
examples have been reported previously [12–17,22,23]. Phos-
phorylation can be ligand-induced, although constitutive phos-
phorylation sites are also present in vivo [23]. Phosphorylation
modulates the transcriptional activity of some of these receptors
[12,14,24,25]. In this report, we provide the ﬁrst evidence that
bothLXRs are phosphorylated and identify a singlemajor phos-
phorylation site at serine 198 in LXRa. Interestingly, this site is
conserved among species and between LXRa and LXRb. While
the present study has focused on LXRa, it seems likely that this
same site may be a target for phosphorylation in LXRb. Serine
198 is characteristic of a MAPK phosphorylation site, but the
relevant kinase remains to be deﬁnitively identiﬁed.
Although LXR phosphorylation may have a role in regulat-
ing receptor function, we have not yet been able to determine
the purpose of this modiﬁcation. Surprisingly, LXRa S198A
did not alter the ability of the receptor to bind LXR response
elements in DNA or to transactivate a reporter gene in trans-
fection assays. It also did not aﬀect the expression of several
known LXR target genes in cultured macrophages and did
not alter receptor activation by LXR ligand. Speciﬁcally, there
was no diﬀerence in the ability of the mutant LXR receptor to
activate the FAS promoter, upregulate the reverse cholesterol
transporters ABCA1/G1, or repress LPS-induced stimulation
of iNOS. It remains possible that phosphorylation of LXRs
may be important for tissue-speciﬁc gene expression, response
to nutritional or environmental cues, receptor stability, or
interactions with other nuclear proteins (e.g. coactivators/core-
pressors, histones).
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